Table 2.
Sampling time point and env sequences
| Subject ID and env sequence type | Time point (in days after EDI)/no. of partial env sequence haplotypesa |
Total no. of sequences (UDS/SGS) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||
| K6 | ||||||||||
| UDS | 219/8 | 95 (8/87) | ||||||||
| SGS | 124/14 | 180/23 | 219/38 | 261/12 | ||||||
| S1 | ||||||||||
| UDS | 85/7 | 167 (7/160) | ||||||||
| SGS | 85/31 | 155/30 | 205/27 | 232/25 | 351/25 | 591/22 | ||||
| D2 | ||||||||||
| UDS | 325/39 | 164 (39/125) | ||||||||
| SGS | 45/22 | 220/24 | 325/26 | 463/24 | 2118/29b | |||||
| K9 | ||||||||||
| UDS | 231/16 | 259/2 | 443/2 | 46 (20/26) | ||||||
| SGS | 136/14 | 315/12 | ||||||||
| P2 | ||||||||||
| UDS | 86/4 | 931/46 | 1015/58 | 277 (108/169) | ||||||
| SGS | 86/22 | 413/25 | 469/9 | 546/25 | 696/24 | 931/28 | 1015/22 | |||
| R5 | ||||||||||
| UDS | 85/5 | 259/5 | 302/2 | 402/2 | 457/16 | 522/5 | 591/11 | 667/19 | 730/11 | 76 (76/0) |
| SGS | ||||||||||
| G5 | ||||||||||
| UDS | 56/14 | 196/11 | 408/2 | 604/9 | 840/1 | 869/9 | 932/26 | 72 (72/0) | ||
| SGS | ||||||||||
a
Numbers indicate the day of sampling since EDI and the number of sequences available at each time point. For NAb rows, numbers indicate the day of sampling since EDI.
b
Under antiretroviral therapy. Blank cells indicate that data were unavailable.